Previous 10 | Next 10 |
Biodesix went public late in 2020 as investors had real concerns from the start. Shares did really well since the offering as the company reported strong revenue numbers driven by Covid-19, although it did not translate into earnings yet. This makes me cautious, as shares have fal...
Biodesix and Seer to discuss combined efforts to utilize Seer Proteograph™ Product Suite to drive novel proteomic insights for translational research Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company, today announced in partnership ...
Biodesix (BDSX) jumps 6% premarket after announcing that its SARS CoV-2 Neutralization Antibody Test (cPass Neutralization Test Kit, GenScript Inc.) is now commercially available.The test uses ELISA technology to detect circulating neutralizing antibodies against the receptor bindin...
Detection of circulating neutralizing antibodies produced in response to COVID-19 vaccination and infection may benefit immunocompromised individuals. Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today an...
Biodesix (BDSX) announces a strategic partnership with Datavant, a leader in helping healthcare organizations safely connect their data and provides solutions to help protect, match, and share health data. Through this partnership, Biodesix will anonymize the lung cancer portion of ...
Biodesix intends to make its databank and linked data accessible to research and biopharma partners Biodesix, Inc. (Nasdaq: BDSX), a leading lung cancer diagnostic solutions company, announced a strategic partnership with Datavant, a leader in helping healthcare orga...
Biodesix (BDSX) announces that the first patient has been enrolled in the company's BEACON-Lung study aimed to evaluate biomarkers to predict overall survival and early progression outcomes in treatment-naïve advanced stage non-small cell lung cancer ((NSCLC)) patients with high PD-...
First Patient Enrolled in Biodesix and Addario Lung Cancer Medical Institute Study Aiming to Predict Patient Survival Using a Blood-based Biomarker Study will evaluate the use of a blood-based biomarker to predict outcomes in high PD-L1 expressing non-small cell lung cancer pati...
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer of Biodesix, will present at the William Blair 41st Annual Growth Stock Conference being held virtually June 1-3, 202...
Image source: The Motley Fool. Biodesix, Inc. (NASDAQ: BDSX) Q1 2021 Earnings Call May 11, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Biodesix, Inc. (BDSX) Q1 2021 Earnings Call Transcript
News, Short Squeeze, Breakout and More Instantly...
Awarding Excellence in Company Culture Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, is honored to announce it has been named to Inc. Magazine’s Best Workplaces list . The ranking is a result of a comprehensive, data-driven measurement pro...
Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer, will participate in two upcoming investor conferences: William Blair 44 th Annual Growth Stock Conference Presentation and 1x1...
Data highlights ability of the Nodify XL2 test to identify benign nodules in patients with emphysema Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, announced that new data will be presented today at the 2024 American Thoracic Society ...